HEP DART 2019: Frontiers in Drug Development for Hepatology
HEP DART 2019: Frontiers in Drug Development for Hepatology
批准号:
9914390
负责人:
Charles M Rice
金额:
$0.85万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-11-20 至 2020-10-31
关键词:
AccreditationAddressAdolescentAreaAtmosphereAwardBiologyCategoriesChemistryClinicalClinical ResearchCommunitiesDevelopmentDiseaseDisease OutcomeDoctor of PhilosophyEducational workshopEnsureEpidemiologyEventFacultyFibrosisFutureGrantGuidelinesHIVHealth PersonnelHealth ProfessionalHepatitisHepatitis B TherapyHepatitis B VirusHepatitis C virusHepatologyInfectionInternationalKnowledgeLearningLiver diseasesMalignant NeoplasmsMedicalMinorityNursesOralPathogenesisPediatricsPharmacologyPhysician AssistantsPhysiciansPopulationPostdoctoral FellowPrimary carcinoma of the liver cellsProcessRegimenResearch PersonnelRoleScholarshipScientistTherapeuticTrainingTravelTreatment ProtocolsTreatment outcomeUniversitiesVaccinationVaccinesViral hepatitisVirusVirus DiseasesWomanchronic liver diseaseclinical developmentco-infectioncontinuing medical educationcostdrug developmentfrontiergraduate studentimprovedinterestliver infectionnonalcoholic steatohepatitisnovelnovel markernovel therapeuticsposterssymposiumtherapeutic developmenttherapeutic vaccinetherapy developmentvaccine developmentvaccinology
中文摘要
摘要/项目摘要:
HEP DART:肝病药物开发前沿是一个每两年一次的独立会议
过去 24 年来吸引了至少 250 名与会者。 HEP DART 向任何感兴趣的人开放
病毒性肝炎和慢性肝病的治疗。本次会议的内容被制定为
主要感兴趣的是科学家和临床研究人员,重点关注药物开发和
疫苗学。 HEP DART 2019 的目的是聚集临床医生、研究人员、基础科学家、护士
和医师助理一起提高我们对正在进行的药物开发的了解
病毒性肝炎(HBV、HCV、HDV、HAV 和 HEV)、非酒精性肝炎的治疗过程
脂肪性肝炎(NASH)和肝细胞癌(HCC)。 HEP DART 将独特地融合
生物学、化学、药理学和临床研究领域为科学界提供
随着对肝脏感染治疗当前和未来挑战的更多了解,
疾病和癌症。目标:(1) 突出抗病毒性肝炎药物开发的进展
如乙型肝炎病毒、丙型肝炎病毒和丁型肝炎病毒。 (2)描述乙型肝炎治疗策略的最新进展。 (3)
重点介绍针对 NASH、纤维化和 HCC 的药物开发进展。 (4)描述小说
病毒性肝炎、肝病和治疗结果的生物标志物。 (5) 回顾目前的治疗方法并
病毒性肝炎疫苗接种指南;描述改进治疗方案的进展。 (6)
了解 HBV 感染和 NASH 对儿科和青少年群体的影响。 (7)
评估疫苗和治疗性疫苗在病毒性肝炎、NASH 和 NASH 未来治疗中的作用
HIV合并感染。 (8)了解HDV、HAV、HEV的流行病学和发病机制。
方法:HEP DART 2019 包括四天的科学演讲,以口头形式进行
通过非并发会话的海报演示格式。埃默里大学办公室
继续医学教育指定 HEP DART 可获得最多 24 个 1 类学分
AMA 医师认可奖。 HEP DART 提供轻松且科学的刺激
为博士和医学博士提供交流和共同学习的氛围。请求支持以帮助支付费用
为年轻研究者、妇女、有色人种和其他群体提供奖学金和旅费补助的费用
代表人数不足。
英文摘要
Abstract/ Project summary:
HEP DART: Frontiers in Drug Development for Hepatology is an independent biennial conference
attracting at least 250 attendees for the past 24 years. HEP DART is open to anyone interested in
therapies for viral hepatitis and chronic liver disease. The content of this conference was developed to
interest primarily scientists and clinical researchers with a focus on drug development and
vaccinology. The aim of HEP DART 2019 is to assemble clinicians, researchers, basic scientists, nurses
and physician assistants together to advance our knowledge of the ongoing drug development
processes in the treatment of viral hepatitis (HBV, HCV, HDV, HAV and HEV), non‐‐‐alcoholic
steatohepatitis (NASH) and hepatocellular carcinoma (HCC). HEP DART will uniquely blend the
areas of biology, chemistry, pharmacology and clinical research to provide the scientific community
with an increased understanding of the current and future challenges in therapeutics for liver infection,
disease and cancer. OBJECTIVES: (1) Highlight advances in drug development against viral hepatitis
such as HBV, HCV, and HDV. (2) Describe the latest developments in HBV curative strategies. (3)
Highlight advances in drug development against NASH, fibrosis and HCC. (4) Describe novel
biomarkers for viral hepatitis, liver disease, and treatment outcomes. (5) Review current treatment and
vaccination guidelines for viral hepatitis; describe advancements in improved treatment regimens. (6)
Understand the consequences of HBV infection and NASH in pediatrics and adolescent populations. (7)
Assess the role of vaccines and therapeutic vaccines in future therapies for viral hepatitis, NASH, and
co‐‐‐infections with HIV. (8) Understand the epidemiology and pathogenesis of HDV, HAV and HEV.
METHODS: HEP DART 2019 comprises four days of scientific presentations, delivered in both oral
and poster presentations formats via non‐‐‐concurrent sessions. Emory University, Office of
Continuing Medical Education designates HEP DART for a maximum 24 category 1 credits toward the
AMA Physician’s Recognition Award. HEP DART provides a relaxed and scientifically stimulating
atmosphere for both PhDs and MDs to network and learn together. Support is requested to help defray
costs of scholarships and travel grants for young investigators, women, visible minorities and other
under‐‐‐represented delegates.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Employing viruses to unravel the functional significance of the m5C epitranscriptome
-
批准号:10638533
-
项目类别:
-
资助金额:$66.0万
-
财政年份:2023
-
负责人:Charles M Rice
-
依托单位:
Elucidating the mechanism by which ADAR1 prevents autoimmunity against self RNA
-
批准号:10667182
-
项目类别:
-
资助金额:$25.43万
-
财政年份:2023
-
负责人:Charles M Rice
-
依托单位:
Tracking SARS-CoV-2 one molecule at a time: Spatiotemporal investigation of coronavirus replication dynamics and host response in single cells in vitro and in vivo
-
批准号:10446423
-
项目类别:
-
资助金额:$63.76万
-
财政年份:2022
-
负责人:Charles M Rice
-
依托单位:
A clear view of encephalitis: a single cell approach to determine the basis of flaviviral pathogenesis in the central nervous system
-
批准号:10553697
-
项目类别:
-
资助金额:$62.82万
-
财政年份:2022
-
负责人:Charles M Rice
-
依托单位:
Tracking SARS-CoV-2 one molecule at a time: Spatiotemporal investigation of coronavirus replication dynamics and host response in single cells in vitro and in vivo
-
批准号:10570297
-
项目类别:
-
资助金额:$61.93万
-
财政年份:2022
-
负责人:Charles M Rice
-
依托单位:
Scientific Core: BSL3 Virology and Animal Models
-
批准号:10327991
-
项目类别:
-
资助金额:$145.45万
-
财政年份:2022
-
负责人:Charles M Rice
-
依托单位:
Scientific Core: BSL3 Virology and Animal Models
-
批准号:10841239
-
项目类别:
-
资助金额:$98.31万
-
财政年份:2022
-
负责人:Charles M Rice
-
依托单位:
A clear view of encephalitis: a single cell approach to determine the basis of flaviviral pathogenesis in the central nervous system
-
批准号:10446620
-
项目类别:
-
资助金额:$68.19万
-
财政年份:2022
-
负责人:Charles M Rice
-
依托单位:
Virology Core
-
批准号:10513915
-
项目类别:
-
资助金额:$528.97万
-
财政年份:2022
-
负责人:Charles M Rice
-
依托单位:
TMEM41B: a pan-flavivirus and pan-coronavirus host factor with antiviral potential
-
批准号:10587597
-
项目类别:
-
资助金额:$46.09万
-
财政年份:2022
-
负责人:Charles M Rice
-
依托单位:
TMEM41B: a pan-flavivirus and pan-coronavirus host factor with antiviral potential
-
批准号:10707260
-
项目类别:
-
资助金额:$61.01万
-
财政年份:2022
-
负责人:Charles M Rice
-
依托单位:
A renewable and genetically tractable human stem cell-derived multicellular platform for the study of fibrotic liver diseases
-
批准号:10576892
-
项目类别:
-
资助金额:$49.43万
-
财政年份:2021
-
负责人:Charles M Rice
-
依托单位:
A renewable and genetically tractable human stem cell-derived multicellular platform for the study of fibrotic liver diseases
-
批准号:10360541
-
项目类别:
-
资助金额:$49.43万
-
财政年份:2021
-
负责人:Charles M Rice
-
依托单位:
A renewable and genetically tractable human stem cell-derived multicellular platform for the study of fibrotic liver diseases
-
批准号:10211567
-
项目类别:
-
资助金额:$50.99万
-
财政年份:2021
-
负责人:Charles M Rice
-
依托单位:
Defining therapeutic drug targets for SARS-CoV-2-specific and pan-coronavirus inhibition
-
批准号:10238377
-
项目类别:
-
资助金额:$48.35万
-
财政年份:2021
-
负责人:Charles M Rice
-
依托单位:
Launching HBV with RNA to assess antiviral resistance and explore fundamental aspects of virus-host biology
-
批准号:10555333
-
项目类别:
-
资助金额:$61.11万
-
财政年份:2020
-
负责人:Charles M Rice
-
依托单位:
Identification of host factors required by the tick-borne Powassan virus
-
批准号:10154884
-
项目类别:
-
资助金额:$25.43万
-
财政年份:2020
-
负责人:Charles M Rice
-
依托单位:
Identification of host factors required by the tick-borne Powassan virus
-
批准号:10307148
-
项目类别:
-
资助金额:$21.19万
-
财政年份:2020
-
负责人:Charles M Rice
-
依托单位:
In search of an HBV cure: novel model systems and targets
-
批准号:10400212
-
项目类别:
-
资助金额:$59.43万
-
财政年份:2019
-
负责人:Charles M Rice
-
依托单位:
In search of an HBV cure: novel model systems and targets
-
批准号:10633080
-
项目类别:
-
资助金额:$59.43万
-
财政年份:2019
-
负责人:Charles M Rice
-
依托单位:
海外基金